Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin versus placebo for exercise-induced hs-cTnI release in chronic heart failure
2015-002673-38Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2015
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of serelaxin in chronic heart failure (CHF) (2 arms), sponsored by Novartis. Started Sep 2015; status: terminated.
02
Drugs
serelaxin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2015-002673-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002673-38.